JP2009294057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009294057A5 JP2009294057A5 JP2008147496A JP2008147496A JP2009294057A5 JP 2009294057 A5 JP2009294057 A5 JP 2009294057A5 JP 2008147496 A JP2008147496 A JP 2008147496A JP 2008147496 A JP2008147496 A JP 2008147496A JP 2009294057 A5 JP2009294057 A5 JP 2009294057A5
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- glut9
- transport
- oocytes
- urat1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019184 SLC2A9 Human genes 0.000 description 98
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 96
- 108091006283 SLC2A9 Proteins 0.000 description 91
- 229940116269 Uric Acid Drugs 0.000 description 89
- 210000000287 oocyte Anatomy 0.000 description 34
- 102100010123 SLC22A12 Human genes 0.000 description 26
- 101710019755 SLC22A12 Proteins 0.000 description 22
- 210000004027 cells Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 208000001721 Renal hypouricemia Diseases 0.000 description 12
- LEHOTFFKMJEONL-RHRFEJLCSA-N N1[14C](=O)NC=2NC(=O)NC=2C1=O Chemical compound N1[14C](=O)NC=2NC(=O)NC=2C1=O LEHOTFFKMJEONL-RHRFEJLCSA-N 0.000 description 10
- 210000004369 Blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000268 renotropic Effects 0.000 description 9
- 230000036826 Excretion Effects 0.000 description 8
- 210000003734 Kidney Anatomy 0.000 description 8
- 230000029142 excretion Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 210000000170 Cell Membrane Anatomy 0.000 description 6
- NIPZZXUFJPQHNH-UHFFFAOYSA-N Pyrazinoic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 108091006660 SLC22A12 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 108010078530 urate transporter Proteins 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 3
- 101710015651 SLC2A9 Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229960002529 Benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N Benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- JKKFKPJIXZFSSB-CBZIJGRNSA-N Estrone sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
- 210000003722 Extracellular Fluid Anatomy 0.000 description 2
- 102000037828 Glucose transporter family Human genes 0.000 description 2
- 108091006272 Glucose transporter family Proteins 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N Pyrazinamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 102000037149 SLC2 Human genes 0.000 description 2
- 108091006189 SLC2 Proteins 0.000 description 2
- 230000036526 Transport Rate Effects 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 201000005569 gout Diseases 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-M orotate Chemical compound [O-]C(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-M 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000008060 renal absorption Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 102100006348 ABCC4 Human genes 0.000 description 1
- 101710024119 ABCC4 Proteins 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 108091006437 Anion exchangers Proteins 0.000 description 1
- 102000037197 Anion exchangers Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000001590 Congenital Abnormality Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-levulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229940072185 DRUGS FOR TREATMENT OF TUBERCULOSIS Drugs 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 230000036081 Excretion rate Effects 0.000 description 1
- 101710036309 GLU9 Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021131 Hypouricaemia Diseases 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- 101710015837 LGALS9 Proteins 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N Losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 Losartan Drugs 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 210000000885 Nephrons Anatomy 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N Probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 108009000226 Purine metabolism Proteins 0.000 description 1
- 229960005206 Pyrazinamide Drugs 0.000 description 1
- 102100011863 SLC17A1 Human genes 0.000 description 1
- 101710027414 SLC17A1 Proteins 0.000 description 1
- 102100010124 SLC22A11 Human genes 0.000 description 1
- 101710019769 SLC22A11 Proteins 0.000 description 1
- 102100010127 SLC22A13 Human genes 0.000 description 1
- 101710019757 SLC22A13 Proteins 0.000 description 1
- 102100020159 SLC22A6 Human genes 0.000 description 1
- 108091006654 SLC22A6 Proteins 0.000 description 1
- 102100010016 SLC22A8 Human genes 0.000 description 1
- 101710019777 SLC22A8 Proteins 0.000 description 1
- 101710019779 SLC22A9 Proteins 0.000 description 1
- 102100000951 SLC2A4 Human genes 0.000 description 1
- 108091006280 SLC2A4 Proteins 0.000 description 1
- 102100019183 SLC2A6 Human genes 0.000 description 1
- 108091006285 SLC2A6 Proteins 0.000 description 1
- 101710040725 SLC5A12 Proteins 0.000 description 1
- 102100020038 SLC5A12 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229960003329 Sulfinpyrazone Drugs 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 201000001509 acute urate nephropathy Diseases 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000002457 bidirectional Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002999 depolarising Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 201000001431 hyperuricemia Diseases 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 101700050207 mctC Proteins 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 101700019200 mrp4 Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003505 mutagenic Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- CSRCBLMBBOJYEX-UHFFFAOYSA-M sodium;2-morpholin-4-ylethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OS(=O)(=O)CCN1CCOCC1 CSRCBLMBBOJYEX-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N β-Hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008147496A JP5574357B2 (ja) | 2008-06-04 | 2008-06-04 | 腎臓尿酸トランスポーター |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008147496A JP5574357B2 (ja) | 2008-06-04 | 2008-06-04 | 腎臓尿酸トランスポーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009294057A JP2009294057A (ja) | 2009-12-17 |
| JP2009294057A5 true JP2009294057A5 (de) | 2011-11-04 |
| JP5574357B2 JP5574357B2 (ja) | 2014-08-20 |
Family
ID=41542362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008147496A Expired - Fee Related JP5574357B2 (ja) | 2008-06-04 | 2008-06-04 | 腎臓尿酸トランスポーター |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5574357B2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201309876D0 (en) * | 2013-06-03 | 2013-07-17 | Tpp Global Dev Ltd | Screening method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3824899B2 (ja) * | 2001-09-21 | 2006-09-20 | 株式会社ヒューマンセルシステムズ | 腎臓及び胎盤型尿酸トランスポーターとその遺伝子 |
| EP1698348A4 (de) * | 2003-11-14 | 2008-02-27 | Human Cell Systems Inc | Mittel zur behandlung/prävention von gefässerkrankungen und hypertonie und untersuchungsverfahren |
-
2008
- 2008-06-04 JP JP2008147496A patent/JP5574357B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wein et al. | SIKs control osteocyte responses to parathyroid hormone | |
| KR102619197B1 (ko) | Hsd17b13 변종 및 이것의 용도 | |
| Caulfield et al. | SLC2A9 is a high-capacity urate transporter in humans | |
| Duan et al. | Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3 | |
| Genau et al. | CUL3-KBTBD6/KBTBD7 ubiquitin ligase cooperates with GABARAP proteins to spatially restrict TIAM1-RAC1 signaling | |
| Bobulescu et al. | Renal transport of uric acid: evolving concepts and uncertainties | |
| Cabral et al. | Absence of the ER cation channel TMEM38B/TRIC-B disrupts intracellular calcium homeostasis and dysregulates collagen synthesis in recessive osteogenesis imperfecta | |
| Yanagihara et al. | NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol η-dependent translesion DNA synthesis | |
| MacDonald et al. | Discovery of a genetic metabolic cause for Mauriac syndrome in type 1 diabetes | |
| Taneera et al. | Silencing of the FTO gene inhibits insulin secretion: An in vitro study using GRINCH cells | |
| Tunalı et al. | A novel mutation in the SLC25A15 gene in a Turkish patient with HHH syndrome: functional analysis of the mutant protein | |
| Jutabha et al. | Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms | |
| US20200399617A1 (en) | B4GALT1 Variants And Uses Thereof | |
| Anzai et al. | Renal solute transporters and their relevance to serum urate disorder | |
| Trevaskis et al. | Src homology 3-domain growth factor receptor-bound 2-like (endophilin) interacting protein 1, a novel neuronal protein that regulates energy balance | |
| Jungtrakoon Thamtarana et al. | Gain of function of malate dehydrogenase 2 and familial hyperglycemia | |
| Hotchkiss et al. | Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines | |
| El-Hoss et al. | Inactivation of the integrin-linked kinase (ILK) in osteoblasts increases mineralization | |
| Song et al. | Species differences in human and rodent PEPT2-mediated transport of glycylsarcosine and cefadroxil in Pichia pastoris transformants | |
| Wang et al. | Differential expression of genes and changes in glucose metabolism in the liver of liver-specific glucokinase gene knockout mice | |
| JP5574357B2 (ja) | 腎臓尿酸トランスポーター | |
| Kim et al. | Identification and functional characterization of a novel mutation of hepatocyte nuclear factor-1α gene in a Korean family with MODY3 | |
| JP2009294057A5 (de) | ||
| Wei et al. | PPTC7 limits mitophagy through proximal and dynamic interactions with BNIP3 and NIX | |
| Kim et al. | Alzheimer’s disease-associated P460L mutation in ephrin receptor type A1 (EphA1) leads to dysregulated Rho-GTPase signaling |